H.C. Wainwright reiterates its Buy recommendation of COVID-19 test maker Co-Diagnostics (CODX -28.8%) with a $20 (195% upside) price target.
Analyst Yi Chen says the company was the first
U.S.-based firm to receive CE Mark certification for its test and recent
FDA policy changes aimed at accelerating the availability of tests in
America should boost sales.
Mr. Chen says the company is currently shipping
its Logix Smart COVID-19 screening test to countries in the U.S.,
Europe, Asia and Australia.
Shares are currently exchanging hands at $6.95, down 68% from its high of $21.67 on March 2.
https://seekingalpha.com/news/3550271-wainwright-reiterates-bullish-call-on-co-diagnostics-sees-195-upside
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.